Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans
Bid Saw UK Pharma Major’s Shares Rise
GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.
You may also be interested in...
The French group is sharpening its focus on specialty care
GlaxoSmithKline is preparing for the long-awaited spin-out of its consumer division later this year but needs to see Shingrix bounce back from its pandemic blues to help the company reignite growth.
Unilever's decision not to increase its £50bn bid for GSK Consumer Healthcare has been widely welcomed by analysts. But they warn that the aborted move for GSK has damaged investor confidence in Unilever’s management.